Treatment of Pelvic Recurrence After Radiotherapy for Cervical Cancer

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Pelvic recurrence after cervical cancer radiotherapy is a significant clinical challenge.
• Limited treatment options and poor prognosis historically characterize this condition.

Purpose of the Study:

• To review current and emerging management strategies for pelvic recurrence in cervical cancer.
• To highlight advances in local therapies, systemic treatments, and personalized medicine.

Main Methods:

• Comprehensive review of literature on salvage surgery, re-irradiation techniques (stereotactic body radiotherapy, image-guided brachytherapy).
• Analysis of systemic therapies including targeted agents (anti-angiogenic drugs, PARP inhibitors, tyrosine kinase inhibitors) and immunotherapy (immune checkpoint inhibitors).
• Discussion of molecular profiling and future therapeutic directions.

Main Results:

• Salvage surgery and re-irradiation offer potential local control with associated toxicities.
• Systemic therapies, particularly targeted agents and immunotherapy (e.g., pembrolizumab, cemiplimab), have shown significant survival improvements in clinical trials.
• Molecular profiling is increasingly guiding personalized treatment selection.

Conclusions:

• Management of recurrent cervical cancer is shifting towards personalized approaches.
• Combination strategies and novel therapies hold promise for achieving durable remission and functional cure.
• Advances in systemic and local treatments are transforming outcomes for patients with recurrent cervical cancer.